Proposed Data Collection Submitted for Public Comment and Recommendations, 37264-37265 [2015-16027]
Download as PDF
<![CDATA[
asabaliauskas on DSK5VPTVN1PROD with NOTICES
37264
Federal Register / Vol. 80, No. 125 / Tuesday, June 30, 2015 / Notices
such as contact information, social
security numbers, case numbers, etc., of
the commenter.
(2) If an individual in making a
statement reveals personal information
(e.g., medical or employment
information) about themselves that
information will not usually be
redacted. The NIOSH Freedom of
Information Act (FOIA) coordinator
will, however, review such revelations
in accordance with the Federal
Advisory Committee Act and if deemed
appropriate, will redact such
information.
(3) If a commenter reveals personal
information concerning a living third
party, that information will be reviewed
by the NIOSH FOIA coordinator, and
upon determination, if deemed
appropriated, such information will be
redacted, unless the disclosure is made
by the third party’s authorized
representative under the Energy
Employees Occupational Illness
Compensation Program Act (EEOICPA)
program.
(4) In general, information concerning
a deceased third party may be disclosed;
however, such information will be
redacted if (a) the disclosure is made by
an individual other than the survivor
claimant, a parent, spouse, or child, or
the authorized representative of the
deceased third party; (b) if it is unclear
whether the third party is living or
deceased; or (c) the information is
unrelated or irrelevant to the purpose of
the disclosure.
The Board will take reasonable steps
to ensure that individuals making
public comment are aware of the fact
that their comments (including their
name, if provided) will appear in a
transcript of the meeting posted on a
public Web site. Such reasonable steps
include: (a) A statement read at the start
of each public comment period stating
that transcripts will be posted and
names of speakers will not be redacted;
(b) A printed copy of the statement
mentioned in (a) above will be
displayed on the table where
individuals sign up to make public
comments; (c) A statement such as
outlined in (a) above will also appear
with the agenda for a Board Meeting
when it is posted on the NIOSH Web
site; (d) A statement such as in (a) above
will appear in the Federal Register
Notice that announces Board and
Subcommittee meetings.
Contact Person for More Information:
Theodore Katz, Designated Federal
Officer, NIOSH, CDC, 1600 Clifton Road
NE., MS E–20, Atlanta, Georgia 30333,
telephone: (513) 533–6800, toll free: 1–
800–CDC–INFO, email: dcas@cdc.gov.
VerDate Sep<11>2014
17:34 Jun 29, 2015
Jkt 235001
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–15925 Filed 6–29–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60–Day–15–15ARG; Docket No. CDC–2015–
0047]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on ‘‘Prevent Hepatitis
Transmission among Persons Who Inject
Drugs’’. The purpose of this study is to
address the high prevalence of HCV
infection by developing an integrated
approach for detection, prevention, care
and treatment of infection among
persons aged 18–30 years who reside in
non-urban counties.
DATES: Written comments must be
received on or before August 31, 2015.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2015–
0047 by any of the following methods:
• Federal eRulemaking Portal:
Regulation.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE.,
MS–D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment should be
submitted through the Federal eRulemaking
portal (Regulations.gov) or by U.S. mail to the
address listed above.
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\30JNN1.SGM
30JNN1
37265
Federal Register / Vol. 80, No. 125 / Tuesday, June 30, 2015 / Notices
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Prevent Hepatitis Transmission Among
Persons Who Inject Drugs—New—
National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease
Control and Prevention (CDC)
Background and Brief Description
Hepatitis C virus (HCV) infection is
the most common chronic blood borne
infection in the United States;
approximately 3 million persons are
chronically infected. Identifying and
reaching persons at risk for HCV
infection is critical to prevent
transmission and treat and cure if
infected. CDC monitors the national
incidence of acute hepatitis C through
passive surveillance of acute,
symptomatic cases of laboratory
confirmed hepatitis C cases. Since 2006,
surveillance data have shown a trend
toward reemergence of HCV infection
mainly among young persons who inject
drugs (PWID) in nonurban counties. Of
the cases reported in 2013 with
information on risk factors 62%
indicated injection drug use as the
primarily through drug treatment
programs and syringe exchange
programs, as well as persons referred to
these sites as a result of referral from
other programs and respondent driven
sampling. Those who consent to
participate will be administered an
eligibility interview questionnaire by
trained field staff. If found eligible, the
participant will take an intervieweradministered survey that includes
information on initiation of drug use,
injection practices, HCV and HIV
infection status, access to prevention
and medical care, desire to receive and
barriers to receiving HCV treatment, and
missed opportunities for hepatitis
prevention. Participants will receive
counselling regarding adherence to
medical and/or drug treatment services
and prevention services. Participants
will be interviewed for a maximum of
5 times within any 12-month interval
during the course of the study: Consent
and interview at enrollment/baseline for
an estimated 60 minutes, and 30-minute
follow-up interviews every 3 months
thereafter. Participants who are
recruited early in the study have more
follow-up interviews than those who are
recruited in the later part of the study
during the 3-year project. However,
recruitment will be spread over 2 years
and on average, the duration of followup is estimated to be one year.
Participation in interviews and
responses to all study questions are
totally voluntary and there is no cost to
respondents other than their time. The
maximum burden is 3,375 hours.
primary risk for acute hepatitis C. The
prevention of HCV infection among
PWIDs requires an integrated approach
including harm reduction interventions,
substance abuse treatment, prevention
of other blood borne infections, and care
and treatment of HCV infection.
The purpose of the proposed study is
to address the high prevalence of HCV
infection by developing and
implementing an integrated approach
for detection, prevention, care and
treatment of infection among persons
aged 18–30 years who reside in nonurban counties. Awardees will develop
and implement a comprehensive
strategy to enroll young non-urban
PWID, collect epidemiological
information, test for HCV infection and
provide linkage to primary care services,
prevention interventions, and treatment
for substance abuse and HCV infection.
In addition to providing HCV testing,
participants will be offered testing for
the presence of co-infections with
hepatitis B virus (HBV) and HIV. Rates
of HCV infection or re-infection will be
evaluated through follow-up blood tests.
Furthermore, adherence to prevention
services and retention in care will be
assessed through follow up interviews.
The project will recruit an estimated
total of 1,500 young PWIDs to enroll
1,000. The participants will be recruited
from settings where young PWIDs
obtain access to care and treatment
services. Recruitment will be direct and
in-person by partnering with local harm
reduction sites. Recruiters will enroll
subjects across recruitment sites
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hrs.)
Total burden
(in hrs.)
Type of respondents
Form name
Young PWIDs ...................................
Eligible young PWIDs .......................
Eligible young PWIDs .......................
Screener ...........................................
Initial Survey .....................................
Follow-up survey ..............................
1500
1000
1000
1
1
4
15/60
60/60
30/60
375
1000
2000
Total ...........................................
...........................................................
........................
........................
........................
3375
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Maryam I. Daneshvar,
Deputy Director, Office of Scientific Integrity,
Office of the Associate Director for Science,
Office of the Director, Centers for Disease
Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–16027 Filed 6–29–15; 8:45 am]
[60Day–15–0666; Docket No. CDC–2015–
0048]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
VerDate Sep<11>2014
17:34 Jun 29, 2015
Jkt 235001
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
ACTION:
Notice with comment period.
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on the National Healthcare
Safety Network (NHSN). NHSN is a
SUMMARY:
E:\FR\FM\30JNN1.SGM
30JNN1
]]>Agencies
[Federal Register Volume 80, Number 125 (Tuesday, June 30, 2015)]
[Notices]
[Pages 37264-37265]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-16027]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60-Day-15-15ARG; Docket No. CDC-2015-0047]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing efforts to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies to take this opportunity to comment on proposed and/or
continuing information collections, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on ``Prevent
Hepatitis Transmission among Persons Who Inject Drugs''. The purpose of
this study is to address the high prevalence of HCV infection by
developing an integrated approach for detection, prevention, care and
treatment of infection among persons aged 18-30 years who reside in
non-urban counties.
DATES: Written comments must be received on or before August 31, 2015.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2015-
0047 by any of the following methods:
Federal eRulemaking Portal: Regulation.gov. Follow the
instructions for submitting comments.
Mail: Leroy A. Richardson, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road,
NE., MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to Regulations.gov, including any personal information
provided. For access to the docket to read background documents or
comments received, go to Regulations.gov.
Please note: All public comment should be submitted through the
Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact the Information Collection Review Office,
Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS-
D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; (d) ways to
minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology; and (e) estimates of capital or start-
up costs and costs of operation, maintenance, and purchase of services
to provide information. Burden means the total time, effort, or
financial resources expended by persons to generate, maintain, retain,
disclose or provide information to or for a Federal agency. This
includes the time needed to review instructions; to develop, acquire,
install and utilize technology and systems for the purpose of
[[Page 37265]]
collecting, validating and verifying information, processing and
maintaining information, and disclosing and providing information; to
train personnel and to be able to respond to a collection of
information, to search data sources, to complete and review the
collection of information; and to transmit or otherwise disclose the
information.
Proposed Project
Prevent Hepatitis Transmission Among Persons Who Inject Drugs--New--
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control and Prevention (CDC)
Background and Brief Description
Hepatitis C virus (HCV) infection is the most common chronic blood
borne infection in the United States; approximately 3 million persons
are chronically infected. Identifying and reaching persons at risk for
HCV infection is critical to prevent transmission and treat and cure if
infected. CDC monitors the national incidence of acute hepatitis C
through passive surveillance of acute, symptomatic cases of laboratory
confirmed hepatitis C cases. Since 2006, surveillance data have shown a
trend toward reemergence of HCV infection mainly among young persons
who inject drugs (PWID) in nonurban counties. Of the cases reported in
2013 with information on risk factors 62% indicated injection drug use
as the primary risk for acute hepatitis C. The prevention of HCV
infection among PWIDs requires an integrated approach including harm
reduction interventions, substance abuse treatment, prevention of other
blood borne infections, and care and treatment of HCV infection.
The purpose of the proposed study is to address the high prevalence
of HCV infection by developing and implementing an integrated approach
for detection, prevention, care and treatment of infection among
persons aged 18-30 years who reside in non-urban counties. Awardees
will develop and implement a comprehensive strategy to enroll young
non-urban PWID, collect epidemiological information, test for HCV
infection and provide linkage to primary care services, prevention
interventions, and treatment for substance abuse and HCV infection. In
addition to providing HCV testing, participants will be offered testing
for the presence of co-infections with hepatitis B virus (HBV) and HIV.
Rates of HCV infection or re-infection will be evaluated through
follow-up blood tests. Furthermore, adherence to prevention services
and retention in care will be assessed through follow up interviews.
The project will recruit an estimated total of 1,500 young PWIDs to
enroll 1,000. The participants will be recruited from settings where
young PWIDs obtain access to care and treatment services. Recruitment
will be direct and in-person by partnering with local harm reduction
sites. Recruiters will enroll subjects across recruitment sites
primarily through drug treatment programs and syringe exchange
programs, as well as persons referred to these sites as a result of
referral from other programs and respondent driven sampling. Those who
consent to participate will be administered an eligibility interview
questionnaire by trained field staff. If found eligible, the
participant will take an interviewer-administered survey that includes
information on initiation of drug use, injection practices, HCV and HIV
infection status, access to prevention and medical care, desire to
receive and barriers to receiving HCV treatment, and missed
opportunities for hepatitis prevention. Participants will receive
counselling regarding adherence to medical and/or drug treatment
services and prevention services. Participants will be interviewed for
a maximum of 5 times within any 12-month interval during the course of
the study: Consent and interview at enrollment/baseline for an
estimated 60 minutes, and 30-minute follow-up interviews every 3 months
thereafter. Participants who are recruited early in the study have more
follow-up interviews than those who are recruited in the later part of
the study during the 3-year project. However, recruitment will be
spread over 2 years and on average, the duration of follow-up is
estimated to be one year.
Participation in interviews and responses to all study questions
are totally voluntary and there is no cost to respondents other than
their time. The maximum burden is 3,375 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondents Form name respondents responses per response (in (in hrs.)
respondent hrs.)
----------------------------------------------------------------------------------------------------------------
Young PWIDs................... Screener........ 1500 1 15/60 375
Eligible young PWIDs.......... Initial Survey.. 1000 1 60/60 1000
Eligible young PWIDs.......... Follow-up survey 1000 4 30/60 2000
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 3375
----------------------------------------------------------------------------------------------------------------
Maryam I. Daneshvar,
Deputy Director, Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2015-16027 Filed 6-29-15; 8:45 am]
BILLING CODE 4163-18-P
